In this week's Homerun Slides, takeaways from the EMPA-REG Trial with empagliflozin, the LEADER Trial and the SUSTAIN-6 Trial.

Acute regulation of gluconeogenesis: Prior to discovery of the transcriptional mechanisms described earlier, the control of hepatic glucose metabolism was examined in great detail on the basis of substrate, allosteric, and posttranslational modification. These factors alter gluconeogenic flux rapidly (seconds to minutes) and are a critical first response to increased glucose demand.

About 6-7 years ago, Dr. Oz came on TV touting the benefit of reservatrol for weight loss, and overnight sales went through the roof. He had his own brand and pretty soon every nutritional company had their product on the market. Just like every nutritional product, it worked for motivated …

Theory proposed that type 2 diabetes can be reversed in the short term with medical approaches over bariatric surgeries.

Changes in gut microbiome may improve blood glucose levels in obese

Continuous glucose monitoring may reduce hypoglycemia fear.

Study reported SGLT2 Inhibitors monotherapy might not lead to DKA events as opposed to insulin therapy.

Risk of type 2 diabetes heightened in elderly women with increase in statin dose.

Epalrestat, an AKR1B1 inhibitor for diabetic patients inhibits progression of BLBC

Which one of the following is an advantage of a glucagon-like peptide-1 (GLP-1) receptor agonist over mealtime insulin? A. Less hypoglycemia B. Fewer injections C. Less weight gain D. All of the above Follow the link to see the correct answer!